ClinicalTrials.gg
CompletedNCT02963311ORION-2Updated May 18, 2020Results posted

A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

A Phase 2 interventional study of ALN-PCSSC and Standard of Care in Homozygous Familial Hypercholesterolemia, sponsored by The Medicines Company. Completed at 3 sites in 3 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-05-18.

Sponsored by The Medicines Company (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Homozygous Familial Hypercholesterolemia with a site in United States — 7 open to participants now, 9 under way, 4 of them phase 3. Homozygous Familial Hypercholesterolemia · United States.

Enrollment
25th of 31
9 · median 29
Started
2016
with 3 others
Phase 2
8 of 36
none open now
Registered
17th of 36
by date

Among the 36 studies in Homozygous Familial Hypercholesterolemia with a site in United States, this one is the 25th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2016, is one of 8 in phase 2, and was the 17th registered.

Homozygous Familial Hypercholesterolemia

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

Browse Homozygous Familial Hypercholesterolemia studies →

Open to participants now

7 of the 36 studies in Homozygous Familial Hypercholesterolemia with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Homozygous Familial Hypercholesterolemia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, and efficacy of ALN-PCSSC in participants with homozygous familial hypercholesterolemia.

03

Conditions studied

  • Homozygous Familial Hypercholesterolemia
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females, ≥12 years of age with a diagnosis of homozygous familial hypercholesterolemia by genetic confirmation or a clinical diagnosis based on a history of an untreated low-density lipoprotein cholesterol (LDL-C) concentration >500 mg/deciliter (dL) [13 millimoles/liter (mmol/L)] together with either xanthoma before 10 years of age or evidence of heterozygous familial hypercholesterolemia in both parents.
  • Stable on a low-fat diet.
  • Stable on pre-existing, lipid-lowering therapies (such as statins, cholesterolabsorption inhibitors, bile-acid sequestrants, or combinations thereof) for at least 4 weeks with no planned medication or dose change for the duration of study participation.
  • Fasting central lab LDL-C concentration >130 mg/dL (3.4 mmol/L) and triglyceride concentration \<400 mg/dL (4.5 mmol/L).
  • Body weight of 40 kilograms (kg) or greater at screening.

Exclusion criteria

Exclusion Criteria:

  • LDL or plasma apheresis within 8 weeks prior to the screening visit, and no plan to receive it during the study because of the attendant difficulty in maintaining stable concentrations of LDL-C while receiving apheresis.
  • Use of mipomersen or lomitapide therapy within 5 months of screening.
  • Previous treatment with monoclonal antibodies directed towards PCSK9 within 8 weeks of screening.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    ALN-PCSSC

    300 milligrams (mg) administered subcutaneous (SC) on Day 1. Participants with a mean serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels not suppressed by \>70% at Day 60 or Day 90, as compared to baseline, will receive a second dose at Day 90 or Day 104, respectively, based on PCSK9 levels from the previous visit. Participants also received standard of care as background therapy.

    Drug: ALN-PCSSC · Drug: Standard of Care

Interventions

  • ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections.

    Also known as: PCSK9 synthesis inhibitor

  • DrugStandard of Care

    Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.

06

What researchers measure

Primary outcomes

  1. Percentage Change From Day 1 to Day 90 in LDL-C

    Due to the small number of subjects, and the fact that the data are not normally distributed, the data are presented as descriptive statistics with no inferential and limited summary statistics presented.

    Time frame: Day 1, Day 90

  2. Percentage Change From Day 1 to Day 180 (or Final Visit) in LDL-C

    Time frame: Day 1, Day 180 (or Final Visit)

Secondary outcomes

  1. Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in LDL-C

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

  2. Percentage Change From Day 1 to Day 60 and to Day 90 in PCSK9

    Time frame: Day 1, Day 60, Day 90

  3. Absolute Change From Day 1 to Day 60 and to Day 90 in PCSK9

    Time frame: Day 1, Day 60, Day 90

  4. Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Total Cholesterol

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

  5. Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Total Cholesterol

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

  6. Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Triglycerides

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

  7. Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Triglycerides

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

  8. Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in HDL-C

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

  9. Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in HDL-C

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

  10. Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Non-HDL-C

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

  11. Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Non-HDL-C

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

  12. Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in VLDL-C

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

  13. Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in VLDL-C

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

  14. Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Apolipoprotein A1

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

  15. Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Apolipoprotein A1

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

  16. Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Apolipoprotein B

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

  17. Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Apolipoprotein B

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

  18. Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Lipoprotein-a

    The reported percent change value is the per participant calculated Mean.

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

  19. Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Lipoprotein-a

    Time frame: Day 1, Day 90, Day 180 (or Final Visit)

07

Results

Posted May 18, 2020

Participant flow

Participant flow — Overall Study
MilestoneInclisiran
Started9
Completed4
Not completed5
Withdrew: Withdrawal by subject1
Withdrew: Screen failure4

Outcome measures

PrimaryPercentage Change From Day 1 to Day 90 in LDL-C

Due to the small number of subjects, and the fact that the data are not normally distributed, the data are presented as descriptive statistics with no inferential and limited summary statistics presented.

Time frame:
Day 1, Day 90
Reported as:
Mean · percent change
Percentage Change From Day 1 to Day 90 in LDL-C
percent changeInclisiran
Percentage Change From Day 1 to Day 90 in LDL-C-12.26 (-43.75 to 19.24)
PrimaryPercentage Change From Day 1 to Day 180 (or Final Visit) in LDL-C
Time frame:
Day 1, Day 180 (or Final Visit)
Reported as:
Mean · percent change
Percentage Change From Day 1 to Day 180 (or Final Visit) in LDL-C
percent changeInclisiran
Percentage Change From Day 1 to Day 180 (or Final Visit) in LDL-C-20.96 (-49.97 to 8.05)
SecondaryAbsolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in LDL-C
Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · mg/dL
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in LDL-C
mg/dLInclisiran
Day 90-56.3 ± 115.18
Day 180-105.3 ± 116.44
SecondaryPercentage Change From Day 1 to Day 60 and to Day 90 in PCSK9
Time frame:
Day 1, Day 60, Day 90
Reported as:
Mean · percent change
Percentage Change From Day 1 to Day 60 and to Day 90 in PCSK9
percent changeInclisiran
Day 60-64.9 ± 18.33
Day 90-59.0 ± 16.46
SecondaryAbsolute Change From Day 1 to Day 60 and to Day 90 in PCSK9
Time frame:
Day 1, Day 60, Day 90
Reported as:
Mean · ng/mL
Absolute Change From Day 1 to Day 60 and to Day 90 in PCSK9
ng/mLInclisiran
Day 60-654.1 ± 564.67
Day 90-602.3 ± 559.61
SecondaryPercentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Total Cholesterol
Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · percent change
Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Total Cholesterol
percent changeInclisiran
Day 90-13.9 ± 14.84
Day 180-19.8 ± 13.68
SecondaryAbsolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Total Cholesterol
Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · mg/dL
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Total Cholesterol
mg/dLInclisiran
Day 90-77.8 ± 103.41
Day 180-118.0 ± 103.52
SecondaryPercentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Triglycerides
Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · percent change
Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Triglycerides
percent changeInclisiran
Day 90-21.0 ± 30.99
Day 180-20.13 ± 11.67
SecondaryAbsolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Triglycerides
Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · mg/dL
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Triglycerides
mg/dLInclisiran
Day 90-35.5 ± 38.76
Day 180-26.3 ± 24.64
SecondaryPercentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in HDL-C
Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · percent change
Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in HDL-C
percent changeInclisiran
Day 90-12.1 ± 17.98
Day 180-19.8 ± 11.78
SecondaryAbsolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in HDL-C
Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · mg/dL
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in HDL-C
mg/dLInclisiran
Day 90-6.0 ± 9.13
Day 180-9.5 ± 4.73
SecondaryPercentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Non-HDL-C
Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · percent change
Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Non-HDL-C
percent changeInclisiran
Day 90-13.9 ± 14.78
Day 180-19.7 ± 13.93
SecondaryAbsolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Non-HDL-C
Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · mg/dL
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Non-HDL-C
mg/dLInclisiran
Day 90-71.8 ± 97.70
Day 180-108.5 ± 99.38
SecondaryPercentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in VLDL-C
Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · percent change
Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in VLDL-C
percent changeInclisiran
Day 908.5 ± 65.28
Day 18055.5 ± 131.92
SecondaryAbsolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in VLDL-C
Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · mg/dL
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in VLDL-C
mg/dLInclisiran
Day 90-15.5 ± 28.41
Day 180-3.3 ± 37.32
SecondaryPercentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Apolipoprotein A1
Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · percent change
Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Apolipoprotein A1
percent changeInclisiran
Day 90-8.3 ± 12.95
Day 180-14.2 ± 14.44
SecondaryAbsolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Apolipoprotein A1
Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · mg/dL
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Apolipoprotein A1
mg/dLInclisiran
Day 90-11.5 ± 17.52
Day 180-19.8 ± 19.00
SecondaryPercentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Apolipoprotein B
Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · percent change
Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Apolipoprotein B
percent changeInclisiran
Day 90-26.6 ± 14.98
Day 180-25.0 ± 14.50
SecondaryAbsolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Apolipoprotein B
Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · mg/dL
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Apolipoprotein B
mg/dLInclisiran
Day 90-95.3 ± 78.16
Day 180-86.3 ± 72.02
SecondaryPercentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Lipoprotein-a

The reported percent change value is the per participant calculated Mean.

Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · percent change
Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Lipoprotein-a
percent changeInclisiran
Day 90-3.5 ± 15.70
Day 180-11.8 ± 15.15
SecondaryAbsolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Lipoprotein-a
Time frame:
Day 1, Day 90, Day 180 (or Final Visit)
Reported as:
Mean · nmol/L
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Lipoprotein-a
nmol/LInclisiran
Day 9013.5 ± 21.92
Day 180-23.8 ± 52.73

Adverse events

Collected over 18 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inclisiran0/4 (0%)1/4 (25%)3/4 (75%)
Most frequent serious events
Most frequent serious events
EventInclisiran
Angina unstableCardiac disorders1/4
Most frequent other events
Showing 10 of 14
Most frequent other events
EventInclisiran
Angina unstableCardiac disorders1/4
Abdominal pain upperGastrointestinal disorders1/4
Influenza like illnessGeneral disorders1/4
Non-cardiac chest painGeneral disorders1/4
CystitisInfections and infestations1/4
NasopharyngitisInfections and infestations1/4
Limb injuryInjury, poisoning and procedural complications1/4
Road traffic accidentInjury, poisoning and procedural complications1/4
Musculoskeletal painMusculoskeletal and connective tissue disorders1/4
Pain in extremityMusculoskeletal and connective tissue disorders1/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Inclisiran
<=18 years0
Between 18 and 65 years4
>=65 years0
Age, Continuous
Age, Continuous(years)Inclisiran
Mean37.0 ± 13.04
Sex: Female, Male
Sex: Female, Male(Participants)Inclisiran
Female2
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Inclisiran
Hispanic or Latino0
Not Hispanic or Latino4
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Inclisiran
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White4
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Inclisiran
Netherlands1
South Africa3
08

Study locations

3 sites
  • Research Site 201001
    Los Angeles, California 90001, United States
  • Research Site 231001
    Amsterdam, Netherlands
  • Research Site 227001
    Parktown, Johannesburg 2193, South Africa
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Oct 2018, 21 months.

Results were first posted in May 2020, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2016
First posted
Nov 15, 2016
StartActual
Dec 13, 2016
Primary completionActual
Oct 8, 2018
CompletionActual
Oct 8, 2018
Results first posted
May 18, 2020
Last update
May 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02963311
Responsible party
Sponsor
First posted
Nov 15, 2016
Start date
Dec 13, 2016
Primary completion
Oct 8, 2018
Completion
Oct 8, 2018
Results posted
May 18, 2020
Last update
May 18, 2020

Study contacts

Kees Hovingh, MD, PhD
principal investigator · Department of Vascular Medicine, Academic Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion